Biopharmaceutical company DURECT Corporation (NASDAQ: DRRX) has expertise in drug discovery, delivery and development, applying those skills primarily to therapeutics in the fields of pain management, CNS disorders, acute organ injury and metabolic diseases. The company’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. For more information, visit the company’s website at www.durect.com.